



Original

BOX SEQUENCE
PATENT
2750-1316P

IN THE U.S. PATENT AND TRADEMARK OFFICE

RECEIVED

APPLICANT(S): N. ALEXANDROV et al. Conf: 7089

APR 25 2002

APPLICATION NO.: 09/697,145

Group: 1631

TECH CENTER 1600/2900

FILED: October 27, 2000

Examiner: M. SHEINBERG

FOR: SEQUENCE-DETERMINED DNA FRAGMENTS AND
CORRESPONDING POLYPEPTIDES ENCODED THEREBY

AMENDMENT WITH RESPONSE TO RESTRICTION REQUIREMENT

Honorable Commissioner of Patents
Washington, D.C. 20231

April 23, 2002

Sir:

In response to the USPTO communication dated October 23, 2001, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

IN THE SPECIFICATION

Please replace the table on page 1 line 7 with the following amended table:

--

File Name	Date of Creation	File Size
2750-1316P Protein Domain Table	April 23, 2002	2.10 MB
2750-1316P.ST25	April 23, 2002	157 MB

--

Please replace the compact disks labeled "Copy 1" and "Copy 2" filed on November 8, 2000 with the two compact disks labeled "Replacement Copy 1" and "Replacement Copy 2" enclosed herewith.

REMARKS

Sequence Listing

Enclosed herewith in full compliance to 37 C.F.R. §§1.821-1.825 is a Sequence Listing submitted on two (2) identical CD-Rs (labeled "Replacement Copy 1" and "Replacement Copy 2") under 37 C.F.R. §1.821(c) in place of the paper copy. The computer readable form of the Substitute Sequence Listing is submitted herewith on one (1) additional CD-R (labeled "Computer Readable Form") as required by §1.821(e). These three (3) sequence listing files, file "2750-1316P.ST25", on three (3) CD-Rs are identical and in no way introduce new matter into the specification.

The Substitute Sequence Listing has been amended to include SEQ ID NO: 812. SEQ ID NO: 812 is the nucleotide sequence originally described as gene 9 from sequence >6102641, as shown in Table 1 of the Specification.

Restriction Requirement

The examiner has required a restriction between the claims of group I (claims 1-10), group II (claim 11), group III (claim 12), group IV (claims 13-14), group V (claim 15), group VI (claim 16) and group VII (claims 17-20).

Applicants choose to prosecute the claims of group I (claims 1-10). Applicants further elect the nucleotide sequence identified as gene 9 (SEQ ID NO: 812) from sequence >6102641, as described in Table 1 of the Specification.

Favorable action on the claims is requested.


If the examiner has any questions concerning this response which can be resolved by telephone, the examiner is requested to contact the undersigned at (703) 205-8000.

Extension of Time

Pursuant to 37 C.F.R §§ 1.17 and 1.136(a), the applicant respectfully petitions for a five (5) month extension of time for filing a response in connection with the present application and the requirement fee of \$980.00 should be **charged to Deposit Account No. 50-1055**.

If the Primary Deposit Account No. 50-1055 is deficient and non-payment will result in a loss of rights, the Commissioner is hereby authorized in this, concurrent and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,
BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #36,623
Raymond C. Stewart, #21,066
P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachments:

- One (1) CD-R of computer readable form of the Sequence Listing
- Two (2) CD-Rs of the Sequence Listing in place of the Paper Copy and with the amended version of the protein domain table
- One(1) CD-R with the marked up version of the changes made to the protein domain table
- Version of Paragraph Amendments showing changes

RCS/DRN/BCF